Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells

Chemical Research in Toxicology

Volumn 19, Issue 7, 2006, Pages 937-943

  Fan, Yun ^a   Schreiber, Emanuel M ^a   Giorgianni, Angela ^b   Yalowich, Jack C ^b   Day, Billy W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; ETOPOSIDE 2 QUINONE; GLUTATHIONE; HEME; HYDROGEN PEROXIDE; ISOTOPE; MYELOPEROXIDASE; QUINONE DERIVATIVE; SUCCINYLACETONE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CATALYSIS; CATALYST; CELL CULTURE; CELL LYSATE; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; ION TRAP MASS SPECTROMETRY; ISOTOPE LABELING; LEUKEMIA; LIQUID CHROMATOGRAPHY; OXIDATION REDUCTION POTENTIAL; PROTEIN EXPRESSION; RISK FACTOR; TANDEM MASS SPECTROMETRY;

BENZOQUINONES; CATALYSIS; CHROMATOGRAPHY, LIQUID; DNA ADDUCTS; ETOPOSIDE; GLUTATHIONE; HL-60 CELLS; HUMANS; MASS SPECTROMETRY; PEROXIDASE;

EID: 33746211294     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0600595     Document Type: Article

References (40)

1. Pommier, Y., Schwartz, R. E., Zwelling, L. A., and Kohn, K. W. (1985) Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 24, 6406-6410.
2. Stewart, C. F. (1994) Use of etoposide in patients with organ dysfunction: Pharmacokinetic and pharmacodynamic considerations. Cancer Chemother. PharmacoL 34 (Suppl.), S76-S83.
3. Relling, M. V., Nemec, J., Schuetz, J. D., Gonzalez, F. J., and Korzekwa, K. R. (1994) O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol. 45, 352-358.
4. Zhuo, X., Zheng, N., Felix, C. A., and Blair, I. A. (2004) Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab. Dispos. 32, 993-1000.
5. Zheng, N., Felix, C. A., Pang, S., Boston, R., Moate, P., Scavuzzo, J., and Blair, I. A. (2004) Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide Clin. Cancer Res. 10, 2977-2985.
6. Watanabe, Y., Nakajima, M., Ohashi, N., Kume, T., and Yokoi, T. (2003) Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab. Dispos. 31, 589-595.
7. Haim, N., Roman, J., Nemec, J., and Sinha, B. K. (1986) Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide(VM-26). Biochem. Biophys. Res. Commun. 135, 215-220.
8. Haim, N., Nemec, J., Roman, J., and Sinha, B. K. (1987) Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res. 47, 5835-5840.
9. Van Maanen, J. M., Verkerk, U. H., Broersen, J., Lafleur, M. V., De Vries, J., Retel, J., and Pinedo, H. M. (1988) Semi-quinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free Radical Res. Commun. 4, 371-384.
10. Kagan, V. E., Kuzmenko, A. I., Tyurina, Y. Y., Shvedova, A. A., Matsura, T., and Yalowich, J. C. (2001) Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: Role of myeloperoxidase. Cancer Res. 61, 7777-7784.
11. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 233-255.
12. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36, 525-535.
13. Shearer, P., Kapoor, G., Beckwith, J. B., Takashima, J., Breslow, N., and Green, D. M. (2001) Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: A report from the National Wilms Tumor Study Group. J. Pediatr. Hematol. Oncol. 23, 109-111.
14. Wierecky, J., Kollmannsberger, C., Boehlke, I., Kuczyk, M., Schleicher, J., Schleucher, N., Metzner, B., Kanz, L., Hartmann, J. T., and Bokemeyer, C. (2005) Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J. Cancer Res. Clin. Oncol. 131, 255-260.
15. Josting, A., Wiedenmann, S., Franklin, J., May, M., Sieber, M., Wolf, J., Engert, A., and Diehl, V. (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 21, 3440-3446.
16. Libura, J., Slater, D. J., Felix, C. A., and Richardson, C. (2005) Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 105, 2124-2131.
17. Strobl, H., Takimoto, M., Majdic, O., Fritsch, G., Scheinecker, C., Hocker, P., and Knapp, W. (1993) Myeloperoxidase expression in CD34+ normal human hematopoietic cells. Blood 82, 2069-2078.
18. Kagan, V. E., Yalowich, J., Borisenko, G. G., Tyurina, Y. Y., Tyurin, V. A., Thampatty, P., and Fabisiak, J. P. (1999) Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol. Pharmacol. 56, 494-506.
19. Yalowich, J. C., Kagan, V. E., Do, D., Yang, S., Giorgianni, A., McDonald, P., Fan, Y., Day, B. W., Riviere, J., and Wagner, J. R. (2004) Myeloperoxidase-dependent pro-oxidant effects of etoposide: Implications for etoposide-induced leukemogenesis. Proc. Am. Assoc. Cancer Res. 45, 3084.
20. Maellaro, E., Del Bello, B., and Comporti, M. (1996) Protection by ascorbate against apoptosis of thymocytes: Implications of ascorbate-induced nonlethal oxidative stress and poly(ADP)ribosylation. Exp. Cell Res. 226, 105-113.
21. Kagan, V. E., Yalowich, J. C., Day, B. W., Goldman, R., Gantchev, T. G., and Stoyanovsky, D. A. (1994) Ascorbate is the primary reductant of the phenoxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems. Biochemistry 33, 9651-9660.
22. Kagan, V. E., and Tyurina, Y. Y. (1998) Recycling and redox cycling of phenolic antioxidants. Ann. N. Y. Acad. Sci. 854, 425-434.
23. Tyurina, Y. Y., Tyurin, V. A., Yalowich, J. C., Quinn, P. J., Claycamp, H. G., Schor, N. F., Pitt, B. R., and Kagan, V. E. (1995) Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: Protective versus damaging effects of phenolic antioxidants. Toxicol. Appl. Pharmacol 131, 277-288.
24. Maanen, J. M. S., Lafleur, M. V., Westmijze, E. J., van Maanen, J. M., van Schaik, M. A., Lankelma, J., and Retel, J. (1988) Formation of different reaction products with single- and double-stranded DNA by the ortho-quinone and the semi-quinone free radical of etoposide (VP-16-213). J. Natl. Cancer Inst. 80, 1526-1533.
25. Chung, M. H., Kim, H.-S., Ohtsuka, E., Kasai, H., Yamamoto, F., and Nishimura, S. (1991) An endonuclease activity in human polymorphonuclear neutrophils that removes 8-hydroxyguanine residues from DNA. Biochem. Biophys. Res. Commun. 178, 1472-1475.
26. Demple, B., and Harrison, L. (1994) Repair of oxidative damage to DNA: Enzymology and biology. Annu. Rev. Biochem. 63, 915-948.
27. Kingma, P. S., and Osheroff, N. (1997) Apurinic sites are position-specific topoisomerase II poisons. J. Biol. Chem. 272, 1148-1155.
28. Sabourin, M., and Osheroff, N. (2000) Sensitivity of human type II topoisomerase to DNA damage: Stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res. 28, 1947-1954.
29. Pang, S., Zheng, N., Felix, C. A., Scavuzzo, J., Boston, R., and Blair, I. A. (2001) Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J. Mass. Spectrom. 36, 771-781.
30. Pinnix, I. B., Guzman, G. S., Bonkovsky, H. L., Zaki, S. R., and Kinkade, J. M., Jr. (1994) The posttranslational processing of myeloperoxidase is regulated by the availability of heme. Arch. Biochem. Biophys. 312, 447-458.
31. Nonaka, T., Mio, M., Doi, M., and Tasaka, K. (1992) Histamine-induced differentiation of HL-60 cells. The role of cAMP and protein kinase A. Biochem. Pharmacol. 44, 1115-1121.
32. Gantchev, T. G., and Hunting, D. G. (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol. Pharmacol. 53, 422-428.
33. Lovett, B. D., Strumberg, D., Blair, I. A., Pang, S., Burden, D. A., Megonigal, M. D., Rappaport, E. F., Rebbeck, T. R., Osheroff, N., Pommier, Y. G., and Felix, C. A. (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 40, 1159-1170.
34. Yu, L. J., Matias, J., Scudiero, D. A., Hite, K. M., Monks, A., Sausville, E. A., and Waxman, D. J. (2001) P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 29, 304-312.
35. Soucék, P., Anzenbacker, P., Skoumalová, I., and Dvorák, M. (2005) Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells 23, 1417-1422.
36. Manns, D. R. A., Lafleur, M. V. M., Westmijize, E. J., Horn, I. R., Bets, G. J., Schuurhuis, J., Lankelma, J., and Retel, J. (1992) Reactions of glutathione with the catechol, the ortho-quinone and semi-quinone free radical of etoposide. Biochem. Pharmacol. 43, 1761-1768.
37. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 36, 5934-5939.
38. Nguyen, L., Chatelut, E., Chevreau, C., Tranchand, B., Lochon, I., Bachaud, J. M., Pujol, A., Houin, G., Bugat, R., and Canal, P. (1998) Population pharmacokinetics of total and unbound etoposide. Cancer Chemother. Pharmacol. 41, 125-132.
39. Rick, O., Beyer, J., Kingreen, D., Schwella, N., Krusch, A., Schleicher, J., Kirsch, A., Huhn, D., and Siegert, W. (1998) High-dose chemotherapy in germ cell tumours: A large single centre experience. Eur. J. Cancer 34, 1883-1888.
40. Karasavvas, N., Carcamo, J. M., Stratis, G., and Golde, D. W. (2005) Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 105, 4004-4012.